期刊文献+

辛伐他汀对厄贝沙坦药代动力学影响的研究 被引量:7

The influence of simvastatin on the pharmacokinetics of irbesartan in rabbits
下载PDF
导出
摘要 目的探讨辛伐他汀相同剂量(5 mg·kg-1)诱导不同时间(3 d和5 d)对新西兰大白兔体内厄贝沙坦药代动力学的影响。方法 24只新西兰大白兔随机分为4组,分别是:3 d对照组(以2%羧甲基纤维素溶液为对照,单用厄贝沙坦50 mg·kg-1)、5 d对照组(以2%羧甲基纤维素溶液为对照,单用厄贝沙坦50 mg·kg-1)、辛伐他汀3 d和辛伐他汀5d诱导组。采用HPLC-荧光法测定血药浓度,DAS3.0软件进行数据处理,计算药代动力学参数。Cmax和Tmax为实验测得。主要药代动力学参数用SPSS13.0软件包进行统计分析。结果经统计分析,与相应对照组比较,辛伐他汀3 d诱导组厄贝沙坦在兔体内的主要药代参数如AUC、CL、Cmax、T 12等差异无显著性(P>0.05);而辛伐他汀5 d诱导组的主要药代参数AUC(0-36)、AUC(0-∞)、MRT(0-36)、MRT(0-∞)、Cmax明显增加(P<0.05),CL明显降低(P<0.05);辛伐他汀5 d诱导组与辛伐他汀3 d诱导组相比,其主要药代参数AUC(0-36)、AUC(0-∞)、MRT(0-36)、MRT(0-∞)、Cmax增加(P<0.05),CL降低(P<0.05)。结论辛伐他汀诱导3 d对新西兰大白兔体内厄贝沙坦的药代动力学无影响;辛伐他汀诱导5 d明显影响新西兰大白兔体内厄贝沙坦的药代动力学;与辛伐他汀3 d诱导组比,辛伐他汀5 d诱导对新西兰大白兔体内厄贝沙坦的药代动力学影响明显。 Aim To investigate the effect of simvastatin on pharmacokinetics of irbesartan after oral administration of simvastatin 5 mg·kg-1 for 3 days and 5 days respectively.Methods 24 New Zealand white rabbits were divided into 4 groups,randomized as follows:control(3 days),control(5 days),simvastatin for 3 days group and simvastatin for 5 days group.The concentrations of irbesartan were determined by HPLC-fluorescence method.The results of the plasma samples were analysed with the DAS version 3.0(Bontz Inc.,Beijing,China) program to determine the compartment models and the pharmacokinetic parameters,and the statistics were analysed by SPSS 13.0 program.Results Compared with the correspond control,there was no obvious influence on the pharmacokinetic parameters of irbesartan such as AUC,CL,Cmax,T1 2 et al.(P0.05) after inducing with simvastatin(5 mg·kg-1) for 3 days;compared with the correspond control,inducing with simvastatin(5 mg·kg-1) for 5 days,the major pharmacokinetic parameters such as AUC(0-36),AUC(0-∞),MRT(0-36),MRT(0-∞),Cmax were increased obviously(P0.05),and CL decreased obviously(P0.05);simvastatin inducing for 5 days compared with simvastatin inducing for 3 days,the major pharmacokinetic parameters such as AUC(0-36),AUC(0-∞),MRT(0-36),MRT(0-∞),Cmax were increased obviously(P0.05),and CL decreased obviously(P0.05).Conclusions There is no significant influence on the pharmacokinetics of irbesartan after inducing with simvastatin(5 mg·kg-1) for 3 days.There is significant influence on the pharmacokinetics of irbesartan after inducing with simvastatin(5 mg·kg-1) for 5 days.Simvastatin(5 mg·kg-1) inducing for 5 days compared with simvastatin(5 mg·kg-1) inducing for 3 days,there is significant influence on the pharmacokinetics of irbesartan.
出处 《中国药理学通报》 CAS CSCD 北大核心 2012年第5期701-704,共4页 Chinese Pharmacological Bulletin
基金 河北省卫生厅"2010年度医学科学研究重点课题计划"项目(No 20100443 20100122) 河北省人力资源和社会保障厅留学回国人员科技活动择优资助项目(No 20100313)
关键词 厄贝沙坦 辛伐他汀 血药浓度 药代动力学 HPLC-荧光法 CYP3A4 CYP2C9 P-gp irbesartan simvastatin plasma concentration pharmacokinetics HPLC-fluorescence method CYP3A4 CYP2C9 P-gp
  • 相关文献

参考文献12

  • 1Kashani A,Phillips C O,Foody J M,et al.Risks associated withstatin therapy:a systematic overview of randomized clinical trials[J].Circulation,2006,114:2788-97.
  • 2孔祥,杨解人,郭莉群,周勇.单纯肾性和复合型肾性高血压大鼠主动脉功能的对比研究[J].中国药理学通报,2009,25(2):252-255. 被引量:7
  • 3Foti R S,Rock D A,Wienkers L C,et al.Selection of alternativeCYP3A4 probe substrates for clinical drug interaction studies usingin vitro data and in vivo simulation[J].Drug Metab Dispos,2010,38:981-7.
  • 4Taavitsainen P,Kiukaanniemi K,PelkonenO.In vitro inhibition-screening of human hepatic P450 enzymes by five angioten-sin-Ⅱreceptor antagonists[J].Clin Pharmacol,2000,56:135-40.
  • 5Shakya A K,Al-Hiari Y M,Alhamami O M.Liquid chromatograph-ic determination of irbesartan in human plasma[J].Chromatogr BAnalyt Technol Biomed Life Sci,2007,848(2):245.
  • 6Gonzalez L,Lopez J A,Alonso R M,et al.Fast screening methodfor the determination of angiotensin receptor antagonists in humanplasma by high-performance liquid chromatography with fluorimet-ric detection[J].Chromatogr A,2002,949(1-2):49-60.
  • 7Erb R.Implications of genetic polymorphisms in drug transportersfor pharmacotherapy[J].Cancer Lett,2006,234(1):4-33.
  • 8BourriéM,Meunier V,Berger Y,et al.Role of cytochromeP4502C9 in Irbesartan oxidation by human liver microsomes[J].Drug Metab Dispos,1999,27(2):288-96.
  • 9Weiss J,Sauer A,Divac N,et al.Interaction of angiotensin recep-tor typeⅠblockers with ATP-binding cassette transporters[J].Biopharm Drug Dispos,2010,31(2-3):150-61.
  • 10Bogman K,Peyer AK,Trk M,et al.HMG-CoA reductase inhib-itors and P-glycoprotein modulation[J].Pharmacol,2001,132:1183-92.

二级参考文献8

共引文献6

同被引文献92

  • 1陈永玲,朱家壁,丁义华.HPLC法测定家兔血浆中厄贝沙坦的浓度[J].江苏药学与临床研究,2006,14(3):153-155. 被引量:4
  • 2王明霞,侯娟,吴俊胜,王敏,李巍巍,张俊贞,杜文力.HPLC-荧光法测定人血浆中替米沙坦血药浓度的方法改进[J].中国药房,2007,18(20):1556-1558. 被引量:3
  • 3Sun L, Li XX, Fan HY, et al. Influence of sex differences on the pharmacokinetics of tilidine and its metabolites nortilidine in heahhy Chinese volunteers [J]. J Chin Pharm Sci, 2012, 21 : 93-100.
  • 4中华人民共和国卫生部.医院处方点评管理规范(试行)[S/OL].(2010-02-10).http://www.gov.cn/gzdt/2010-03/04/content-1547080.htm.
  • 5中华人民共和国卫生部.2011年全国抗菌药物临床应用专项整治活动方案[S/OL].(2011-04-19).http://wen-ku.baidu.com/view/fbb60a145foe7cdl842536af.html.
  • 6中华人民共和国卫生部.2012年全国抗菌药物临床应用专项整治活动方案[S/OL].(2012-03-06).http://WWW.gov.cn/gzdt/2012-03/06/content一2084862.htm.
  • 7中华人民共和国卫生部.抗菌药物临床应用管理办法(卫生部令第84号)[S/OL].(2012-4-24).http://www.moh.gov.cn/mohzcfgs/s3576/201205/54645.shtml.
  • 8王婉钢,刘启明.HPLC-荧光检测法测定人血浆中厄贝沙坦的浓度[J].中国药房,2007,18(32):2512-2513. 被引量:10
  • 9Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin[J]. Clin pharmacokinet, 2001,40 (4) : 263 - 281.
  • 10Shakya AK, AI- Hiari YM, Alhamami OM. Liquid chromatographic deter- mination of irbesartan in human plasma[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007,848 (2) : 245.

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部